<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Orthopedics</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>How to grow a startup in the AI era: MedTech Spotlight Korea 2026 </title>
      <description>
        <![CDATA[AI and advanced biotechnology are reshaping South Korea’s med-tech sector, but great technology alone is not enough to build a successful medical device company, speakers said at MedTech Innovator’s Medtech Spotlight: New Impact Korea 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729896</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729896-how-to-grow-a-startup-in-the-ai-era-medtech-spotlight-korea-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Newco/AI-startup-art-concept.webp?t=1774299523" type="image/jpeg" medium="image" fileSize="387241">
        <media:title type="plain">AI startup art concept</media:title>
      </media:content>
    </item>
    <item>
      <title>How to grow a startup in the AI era: MedTech Spotlight Korea 2026 </title>
      <description>
        <![CDATA[AI and advanced biotechnology are reshaping South Korea’s med-tech sector, but great technology alone is not enough to build a successful medical device company, speakers said at MedTech Innovator’s Medtech Spotlight: New Impact Korea 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729811</guid>
      <pubDate>Mon, 23 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729811-how-to-grow-a-startup-in-the-ai-era-medtech-spotlight-korea-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Newco/AI-startup-art-concept.webp?t=1774299523" type="image/jpeg" medium="image" fileSize="387241">
        <media:title type="plain">AI startup art concept</media:title>
      </media:content>
    </item>
    <item>
      <title>Smith+Nephew buying Integrity Orthopaedics for up to $450M</title>
      <description>
        <![CDATA[Smith+Nephew plc (S+N) has agreed to acquire Integrity Orthopaedics Inc. for up to $450 million in a bid to strengthen its shoulder repair portfolio. The move comes as the company looks to accelerate its growth with strategic investments, with the deal expected to be an important step in its ambition in becoming a global leader in sports medicine.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727812</guid>
      <pubDate>Tue, 13 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727812-smithnephew-buying-integrity-orthopaedics-for-up-to-450m</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Stock-merger-illustration.webp?t=1620238968" type="image/png" medium="image" fileSize="458135">
        <media:title type="plain">Stock merger illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Companion Spine gains FDA PMA for DIAM spinal implant</title>
      <description>
        <![CDATA[Companion Spine SAS received premarket approval from the U.S. FDA for its DIAM spinal stabilization system, for treatment of degenerative disc disease. The approval comes as the company recently completed the acquisition of a number of assets from Xtant Medical Holdings Inc., including Paradigm Spine GmbH, as it continues to strengthen its position in providing solutions to treat spinal degenerative conditions.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727074</guid>
      <pubDate>Tue, 16 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727074-companion-spine-gains-fda-pma-for-diam-spinal-implant</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Inflammatory/Back-pain.webp?t=1629406381" type="image/png" medium="image" fileSize="312093">
        <media:title type="plain">Back pain</media:title>
      </media:content>
    </item>
    <item>
      <title>Aesculap clears its legal troubles with $38.5M OIG settlement</title>
      <description>
        <![CDATA[  Aesculap Implant Systems LLC has seen its share of bad news recently, but the company seems to have cleared the legal deck with an agreement to pay $38.5 million per a Nov. 17 announcement by the U.S. attorney’s office for the district of Eastern Pennsylvania.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726198</guid>
      <pubDate>Tue, 18 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726198-aesculap-clears-its-legal-troubles-with-385m-oig-settlement</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/US-law-flag-gavel.webp?t=1593467765" type="image/png" medium="image" fileSize="1749746">
        <media:title type="plain">Judge's gavel with US flag</media:title>
      </media:content>
    </item>
    <item>
      <title>CG Bio, Nexgel developing long-acting drug delivery system</title>
      <description>
        <![CDATA[Nexgel Biotech Co. Ltd. and CG Bio Co. Ltd. agreed to co-develop a thermosensitive polyphosphazene hydrogel-based long-acting drug delivery platform through a new collaboration agreement signed Oct. 31.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725510</guid>
      <pubDate>Tue, 04 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725510-cg-bio-nexgel-developing-long-acting-drug-delivery-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Collaboration-illustration.webp?t=1600375790" type="image/png" medium="image" fileSize="669559">
        <media:title type="plain">Deal illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Customed raises funds for platform to transform orthopedic surgery</title>
      <description>
        <![CDATA[Customed Ltd. has completed its seed funding round, bringing the total capital raised to $6 million. The company has developed a platform which provides orthopedic surgeons with personalized pre-surgical planning and 3D printed surgical tools. The funds will be used to support regulatory approvals in the U.S. and EU, as well as expansion into additional automated orthopedic indications.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725462</guid>
      <pubDate>Thu, 30 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725462-customed-raises-funds-for-platform-to-transform-orthopedic-surgery</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/CustoMED-software-10-30.webp?t=1761859346" type="image/jpeg" medium="image" fileSize="192480">
        <media:title type="plain">Customed software </media:title>
        <media:description type="plain">Customed software provides orthopedic surgeons with personalized pre-surgical planning and 3D printed surgical tools. Credit: Customed Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Johnson &amp; Johnson plans orthopedics break up</title>
      <description>
        <![CDATA[Breaking up isn’t so hard to do, it seems. Just two years after spinning off its consumer products as Kenvue Inc., Johnson & Johnson aims to part ways with its orthopedics unit, which will take up the Depuy Synthes name first created when Synthes Inc. married into the J&J Depuy ortho unit in 2012 for a tidy sum of $19.7 billion. Depuy was itself acquired in 1998.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724919</guid>
      <pubDate>Tue, 14 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724919-johnson-and-johnson-plans-orthopedics-break-up</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/JJ-signage.webp?t=1752701836" type="image/jpeg" medium="image" fileSize="388652">
        <media:title type="plain">Johnson &amp; Johnson signage</media:title>
        <media:description type="plain">Credit: Johnson &amp;amp; Johnson</media:description>
      </media:content>
    </item>
    <item>
      <title>Johnson &amp; Johnson plans orthopedics break up</title>
      <description>
        <![CDATA[  Breaking up isn’t so hard to do, after all. Just two years after spinning off its consumer products as Kenvue Inc., Johnson & Johnson aims to part ways with its orthopedics unit, which will take with it the Depuy Synthes name first created when Synthes Inc. married into the J&J Depuy ortho unit in 2012 for a tidy sum of $19.7 billion. Depuy was itself acquired in 1998.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725214</guid>
      <pubDate>Tue, 14 Oct 2025 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725214-johnson-and-johnson-plans-orthopedics-break-up</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/JJ-signage.webp?t=1752701836" type="image/jpeg" medium="image" fileSize="388652">
        <media:title type="plain">Johnson &amp; Johnson signage</media:title>
        <media:description type="plain">Credit: Johnson &amp;amp; Johnson</media:description>
      </media:content>
    </item>
    <item>
      <title>Ottobock raises €808M in public debut, Billiontoone files for IPO</title>
      <description>
        <![CDATA[Ottobock SE & Co. KGaA got the Frankfurt Stock Exchange on its feet and dancing with Germany’s largest IPO in more than 18 months Oct. 9. The €808 million (US$934.23 million) gave the prosthetics company a market capitalization of €4.2 billion (US$4.88 billion), which rapidly rose as the share price shot up from €66 to €72 at the start of trading. The second med-tech to go public in October should have more company soon, with U.S. molecular diagnostics company Billiontoone Inc. filing Oct. 7 for an IPO with placeholder value of $100 million.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724823</guid>
      <pubDate>Thu, 09 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724823-ottobock-raises-808m-in-public-debut-billiontoone-files-for-ipo</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/IPO-puzzle-pieces.webp?t=1594411157" type="image/png" medium="image" fileSize="214047">
        <media:title type="plain">IPO puzzle pieces</media:title>
      </media:content>
    </item>
    <item>
      <title>EY: Med-tech vital signs robust</title>
      <description>
        <![CDATA[Ernst & Young LLP didn't quite declare the patient cured but saw signs of a strong med-tech recovery after a few years on life support in its annual Pulse of the MedTech Industry report. The global accounting giant particularly called out strength in the cardiovascular, diabetes, robotics and orthopedics segments.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724469</guid>
      <pubDate>Tue, 30 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724469-ey-med-tech-vital-signs-robust</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Respiratory/Lungs-with-alveoli.webp?t=1758058023" type="image/jpeg" medium="image" fileSize="313044">
        <media:title type="plain">Lungs with alveoli</media:title>
      </media:content>
    </item>
    <item>
      <title>Onward Medical’s ARC-IM system improves BP control after SCI</title>
      <description>
        <![CDATA[An international team of researchers has successfully used Onward Medical N.V.’s ARC-IM therapy to develop a neurostimulation system that improves blood pressure stability in patients with spinal cord injuries. According to data from two studies published in <em>Nature</em> and <em>Nature Medicine</em>, the implanted system also led to durable reduction of hypotensive symptoms, resulting in an improvement in the quality of life of patients.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724122</guid>
      <pubDate>Thu, 18 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724122-onward-medicals-arc-im-system-improves-bp-control-after-sci</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Onward-Arc-IM-system-5mar25.webp?t=1741215897" type="image/jpeg" medium="image" fileSize="197021">
        <media:title type="plain">Onward Arc IM system</media:title>
        <media:description type="plain">Onward Arc IM system. Credit: Onward Medical</media:description>
      </media:content>
    </item>
    <item>
      <title>​Ottobock plans 2025 IPO on Frankfurt exchange</title>
      <description>
        <![CDATA[German bionics leader Ottobock SE & KGaA plans to list on the Frankfurt Stock Exchange by the end of the year in an IPO targeting gross proceeds of €100 million (US$117.7 million). Ottobock would be the fourth European company to go public this year, a good sign for the European med-tech market, which had not seen any since the first half of 2022.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724091</guid>
      <pubDate>Mon, 15 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724091-ottobock-plans-2025-ipo-on-frankfurt-exchange</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Businessman-and-IPO-virtual-screen.webp?t=1717791671" type="image/jpeg" medium="image" fileSize="332138">
        <media:title type="plain">Businessman and IPO virtual screen</media:title>
      </media:content>
    </item>
    <item>
      <title>Goodpath accelerates AI development following $18M series A</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[Goodpath Inc., a virtual provider of whole-person care for chronic conditions, raised $18 million in series A financing, led by Massmutual Ventures with participation from Healthy Ventures and current investors. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/723746</guid>
      <pubDate>Fri, 12 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723746-goodpath-accelerates-ai-development-following-18m-series-a</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Venture-funding.webp?t=1588343882" type="image/png" medium="image" fileSize="186259">
        <media:title type="plain">Gold coins and sprouting plants</media:title>
      </media:content>
    </item>
    <item>
      <title>Cohesys Bonetape aims to reconstruct facial surgery</title>
      <description>
        <![CDATA[Cohesys Inc. conducted the first test of its resorbable Bonetape in humans as part of an investigational trial for craniofacial fractures. The tape could eliminate the use of drills and screws in many plastic and reconstructive facial surgeries, potentially simplifying procedures and recovery. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/723187</guid>
      <pubDate>Wed, 20 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723187-cohesys-bonetape-aims-to-reconstruct-facial-surgery</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/bone-tape-20aug25.webp?t=1755725839" type="image/png" medium="image" fileSize="1033113">
        <media:title type="plain">Bone Tape</media:title>
        <media:description type="plain">Cohesys Bonetape could eliminate the use of drills and screws in some facial surgeries. Credit: courtesy Cohesys</media:description>
      </media:content>
    </item>
    <item>
      <title>Onward Medical receives FDA IDE for BP study with ARC-IM system</title>
      <description>
        <![CDATA[Onward Medical NV secured U.S. FDA investigational device exemption (IDE) approval for a pivotal study to assess the safety and efficacy of its implantable spinal stimulation technology, the ARC-IM system. The Empower study BP study will focus on addressing blood pressure instability in patients with spinal cord injury (SCI). ]]>
      </description>
      <guid>http://www.bioworld.com/articles/723176</guid>
      <pubDate>Tue, 19 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723176-onward-medical-receives-fda-ide-for-bp-study-with-arc-im-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Onward-Arc-IM-system-5mar25.webp?t=1741215897" type="image/jpeg" medium="image" fileSize="197021">
        <media:title type="plain">Onward Arc IM system</media:title>
        <media:description type="plain">Onward Arc IM system. Credit: Onward Medical</media:description>
      </media:content>
    </item>
    <item>
      <title>Ceribell alleges EEG patent infringement by Natus</title>
      <description>
        <![CDATA[The reach of the med-tech patent wars now includes devices for electroencephalography thanks to a complaint recently filed by Sunnyvale, Calif.-based Ceribell Inc. with the U.S. International Trade Commission. The company alleged infringement of six of its patents by two units under the Natus umbrella of companies, but this conflict is also under review in Delaware district court, promising a drawn-out conflict that may not resolve for years.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722847</guid>
      <pubDate>Wed, 13 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722847-ceribell-alleges-eeg-patent-infringement-by-natus</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Ceribell-11oct24.webp?t=1728677715" type="image/jpeg" medium="image" fileSize="114735">
        <media:title type="plain">Ceribell</media:title>
        <media:description type="plain">Ceribell point-of-care EEG system. Credit: Ceribell</media:description>
      </media:content>
    </item>
    <item>
      <title>Research details new AI-enhanced 3D ultrasound imaging method</title>
      <description>
        <![CDATA[A research team from Pusan National University has developed a novel deep learning model coined Moglo-Net, designed to enable three-dimensional reconstruction of images from hand-held ultrasound procedures.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722819</guid>
      <pubDate>Mon, 11 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722819-research-details-new-ai-enhanced-3d-ultrasound-imaging-method</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/PNU-AI-ultrasound-11aug25.webp?t=1754949023" type="image/jpeg" medium="image" fileSize="263692">
        <media:title type="plain">PNU AI ultrasound</media:title>
        <media:description type="plain">Moglo-Net tracks the motion of the ultrasound transducer using tissue speckle data without the need for external sensors, creating a clear 3D ultrasound volume for accurate visualization of bodily structures, enabling more efficient and safe medical treatments. Credit: PNU</media:description>
      </media:content>
    </item>
    <item>
      <title>Heartflow prices IPO, Shoulder Innovation joins NYSE</title>
      <description>
        <![CDATA[Like waves crashing on the beach, med-tech IPOs keep on coming. Heartflow Inc. set terms for its IPO on Aug. 1, offering 12.5 million shares at a price range of $15 to $17 per share. At the top of the range, the company could raise a sunny $212.5 million. It plans to list on the Nasdaq with the symbol “HTFL.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/722573</guid>
      <pubDate>Fri, 01 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722573-heartflow-prices-ipo-shoulder-innovation-joins-nyse</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/thumb/Businessman-and-IPO-virtual-screen.webp?t=1717791671" type="image/jpeg" medium="image" fileSize="131045">
        <media:title type="plain">Businessman and IPO virtual screen</media:title>
      </media:content>
    </item>
    <item>
      <title>Globus CEO leaving, analysts see replacement as steady hand</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[Globus Medical Inc. reported the departure of its president and CEO, but sought to quell any concerns about what his leaving augurs for the future of the company.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722071</guid>
      <pubDate>Mon, 21 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722071-globus-ceo-leaving-analysts-see-replacement-as-steady-hand</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/thumb/Merger-game-pieces.webp?t=1578600264" type="image/png" medium="image" fileSize="258633">
        <media:title type="plain">Merger-game-pieces.png</media:title>
      </media:content>
    </item>
    <item>
      <title>Carlsmed aims for $100M+ IPO</title>
      <description>
        <![CDATA[Carlsmed Inc. launched its IPO at a price of $14 to $16 per share for 6.7 million shares, which would raise just over $100.5 million at the midpoint. The spinal surgery technology company could well pull in more money, if recent history provides guidance. Most med-tech IPOs this year have settled at the upper end of their price range, with Caris Life Sciences Inc. notably raising its price twice before going public at $21, a dollar more than the top of its initial range.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721954</guid>
      <pubDate>Tue, 15 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721954-carlsmed-aims-for-100m-ipo</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Going-public-ticker.webp?t=1601061733" type="image/png" medium="image" fileSize="617241">
        <media:title type="plain">Going public ticker</media:title>
      </media:content>
    </item>
    <item>
      <title>Zimmer Biomet in $168M buy of ortho robotics maker Monogram</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[Zimmer Biomet Holdings Inc. reported it is buying orthopedic robotics maker Monogram Technologies Inc. for an upfront payment of $4.04 per share in cash, corresponding to an equity value of approximately $177 million and an enterprise value of about $168 million. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/721943</guid>
      <pubDate>Mon, 14 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721943-zimmer-biomet-in-168m-buy-of-ortho-robotics-maker-monogram</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Stock-merger-illustration.webp?t=1620238968" type="image/png" medium="image" fileSize="458135">
        <media:title type="plain">Stock merger illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Tissium’s polymer solution set to transform nerve repair after FDA nod</title>
      <description>
        <![CDATA[Could the U.S. FDA’s de novo marketing authorization for Tissium SA’s Coaptium Connect, an atraumatic sutureless solution for peripheral nerve repair, signal a transformative shift away from sutures in nerve surgery? Only time will tell.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721141</guid>
      <pubDate>Mon, 30 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721141-tissiums-polymer-solution-set-to-transform-nerve-repair-after-fda-nod</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/tissium-30june25.webp?t=1751320285" type="image/jpeg" medium="image" fileSize="191903">
        <media:title type="plain">tissium</media:title>
        <media:description type="plain">Tissium Coaptium Connect system. Credit: Tissium</media:description>
      </media:content>
    </item>
    <item>
      <title>Tetratherix lists on ASX in $25M IPO</title>
      <description>
        <![CDATA[Tetratherix Ltd. raised AU$45 million (US$25 million) in its IPO on the Australian Securities Exchange (ASX:TTX) to support clinical development of its Tetramatrix polymer biomaterial platform to support bone regeneration, tissue spacing and tissue healing.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721140</guid>
      <pubDate>Mon, 30 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721140-tetratherix-lists-on-asx-in-25m-ipo</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Tetratherix-Tetramatrix-30june25.webp?t=1751318592" type="image/jpeg" medium="image" fileSize="240574">
        <media:title type="plain">Tetratherix Tetramatrix</media:title>
        <media:description type="plain">Tetratherix’s Tetramatrix polymer biomaterial is delivered as a liquid. Credit: Tetratherix</media:description>
      </media:content>
    </item>
    <item>
      <title>Wandercraft secures $75M in series D funds for robotics portfolio</title>
      <description>
        <![CDATA[Wandercraft SAS secured $75 million in funding in a series D round to grow its AI-powered robotics solutions. Funds will be spent on its exoskeletons, Atalante X and Eve, as well as on the industrial development and rollout of Calvin 40, its humanoid robot.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720784</guid>
      <pubDate>Thu, 12 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720784-wandercraft-secures-75m-in-series-d-funds-for-robotics-portfolio</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/06-06-Atalante-X-Wandercraft.webp?t=1654579636" type="image/png" medium="image" fileSize="549867">
        <media:title type="plain">Atalante X Wandercraft</media:title>
        <media:description type="plain">Atalante X, the next-generation exoskeleton for physical therapy from Wandercraft. Copyright: Wandercraft SAS</media:description>
      </media:content>
    </item>
    <item>
      <title>Omada, Caris arrivals continue med-tech IPO hot streak</title>
      <description>
        <![CDATA[Omada Health Inc. rang the opening bell on the New York Stock Exchange on June 6, marking its first day as a public company, but it won’t be the most recent IPO for very long. Continuing the brisk pace seen so far this year, Caris Life Sciences Inc. is hot on its heels with a road show in progress leading up to its expected debut on the Nasdaq next week.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720754</guid>
      <pubDate>Mon, 09 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720754-omada-caris-arrivals-continue-med-tech-ipo-hot-streak</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Nasdaq-Stock-Exchange-HQ-AdobeStock-Editorial.webp?t=1722459418" type="image/jpeg" medium="image" fileSize="376841">
        <media:title type="plain">The Nasdaq Stock Exchange headquarters in New York</media:title>
        <media:description type="plain">Credit: JHVEPhoto - stock.adobe.com
</media:description>
      </media:content>
    </item>
    <item>
      <title>Amber Vcfix spinal system shows promising data</title>
      <description>
        <![CDATA[Amber Implants BV reported no device-related adverse events were seen in any of the patients fitted with its Vcfix spinal system, which treats vertebral compression fractures, at one-year. Data from the first-in-human trial of the device also showed patients experienced a significant reduction in their pain levels. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/720638</guid>
      <pubDate>Tue, 03 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720638-amber-vcfix-spinal-system-shows-promising-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Amber-Implants-VCFix-Spinal-System-3june25.webp?t=1748984268" type="image/jpeg" medium="image" fileSize="146191">
        <media:title type="plain">Amber Implants VCFix Spinal System</media:title>
        <media:description type="plain">Amber Implants VCFix Spinal System. Credit: Amber Implants</media:description>
      </media:content>
    </item>
    <item>
      <title>Alexandra Hospital team patents new AI robotic knee surgery</title>
      <description>
        <![CDATA[A research team led by consultant and orthopedic surgeon Glen Liau Zi Qiang from Alexandra Hospital in Singapore developed a new AI algorithm to improve the accuracy and efficiency of robotic total knee arthroplasty (rTKA) surgery.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720634</guid>
      <pubDate>Tue, 03 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720634-alexandra-hospital-team-patents-new-ai-robotic-knee-surgery</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/AI-knee-surgery-AlexandraHospital-3june25.webp?t=1748983077" type="image/jpeg" medium="image" fileSize="754949">
        <media:title type="plain">AI knee surgery at Alexandra Hospital</media:title>
        <media:description type="plain">A team of medical programmers from Alexandra Hospital in Singapore showcase their patented novel AI-based algorithm for robotic total knee arthroplasty surgery. Left to right: Glen Liau, Ryan Loke and Matthew Ng.
</media:description>
      </media:content>
    </item>
    <item>
      <title>Hinge Health rings NYSE bell as IPO raises $437M</title>
      <description>
        <![CDATA[Hinge Health Inc.’s flexibility produced big rewards as the digital therapy company for physical rehabilitation finally began trading on the NYSE under the symbol HNGE on May 22 after delaying its IPO twice. Hinge co-founders Daniel Perez and Gabriel Mecklenburg rang the opening bell for the stock exchange to celebrate the offering’s $437 million haul.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720269</guid>
      <pubDate>Thu, 22 May 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720269-hinge-health-rings-nyse-bell-as-ipo-raises-437m</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Businessman-and-IPO-virtual-screen.webp?t=1717791671" type="image/jpeg" medium="image" fileSize="332138">
        <media:title type="plain">Businessman and IPO virtual screen</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA gives nod to Orthocell’s 510(k) for nerve repair product</title>
      <description>
        <![CDATA[The U.S. FDA has cleared regenerative medicine company Orthocell Ltd.’s 510(k) for its nerve repair product, Remplir, paving the way to begin commercial operations in the $1.6 billion U.S. nerve repair market.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718894</guid>
      <pubDate>Wed, 09 Apr 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718894-fda-gives-nod-to-orthocells-510k-for-nerve-repair-product</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Orthocell-Remplir-box-9apr25.webp?t=1744229232" type="image/jpeg" medium="image" fileSize="155377">
        <media:title type="plain">Orthocell Remplir</media:title>
        <media:description type="plain">Orthocell Ltd.’s regenerative nerve repair product, Remplir. Credit: Orthocell</media:description>
      </media:content>
    </item>
  </channel>
</rss>
